Podcasts about new therapies

Dr. Ruchira Singh is an Associate Professor and the recipient of the Dean's Professorship in the Department of Ophthalmology at the University of Rochester Medical Center where she also has joint appointments in the Department of Biomedical Genetics and the Center for Visual Science. Ruchira studies eye diseases to understand why some people can't see as well as others, and the knowledge gained can be used to develop new treatments for diseases like age-related macular degeneration and Batten disease, which can cause blindness. When she's not working, Ruchira loves spending time with her two kids. Even the small, everyday moments they spend together doing things like going to McDonalds, the park, or their local library bring her so much joy. Ruchira received a bachelor's degree in computer science from Jawaharlal Nehru Technological University (JNTU) in India, and she completed her graduate studies in Physiology at Kansas State University. Next, Ruchira conducted postdoctoral research in Pharmacology at Yale School of Medicine, followed by a postdoc position in stem cell research at the University of Wisconsin-Madison. She joined the faculty at the University of Rochester in 2014. In this interview, Ruchira discusses her life and science.

Dr. Valentin, radiologist, discusses liver cancer and how the therapy of the TheraSphere Y-90 Glass Microspheres works to help treat cancer in the liver. He will cover how your liver functions, types of liver cancer and the latest treatment options for liver cancer.

Tinnitus remains one of otology's greatest, most challenging, and unsolved clinical problems. In this episode of the BackTable ENT Podcast, Dr. Hamid Djalilian, chair of otolaryngology at University of California Irvine (UCI), joins guest host and fellow otologist Dr. Walter Kutz (UT Southwestern) to discuss contemporary tinnitus therapy. --- This podcast is supported by: PearsonRavitz https://pearsonravitz.com/backtable --- SYNPOSIS First, Dr. Djalilian shares how he got interested in tinnitus. After observing how migraines and tinnitus share many similar triggers, he hypothesized that increased central sensitivity underlies both diseases. He successfully adopted migraine management strategies for his tinnitus patients and found great clinical success. After sharing pathophysiologic similarities between the two diseases, Dr. Djalilian expounds on how he evaluates and treats tinnitus. His discussion includes lifestyle modifications, medication, and emerging surgical therapies. Finally, he advises listeners to think of tinnitus as a manageable condition, rather than a poorly-understood phenomenon. --- TIMESTAMPS 00:00 - Introduction 02:34 - The Challenge of Treating Tinnitus 07:19 - Connecting Tinnitus & Migraine 15:59 - Atypical (Otologic) Migraine & Diagnostic Challenges 19:59 - Managing Tinnitus Triggers 26:27 - Dietary Triggers of Tinnitus 28:44 - The Role of Sleep Quality in Tinnitus 33:04 - Caring for Older Patients with Tinnitus 37:59 - New Therapies for Tinnitus: Sound & Cognitive Behavioral Therapy 44:08 - Neuromodulation: The Future of Tinnitus Therapy? 51:34 - Final Thoughts on Tinnitus Treatment --- RESOURCES BackTable ENT Episode 60 Otologic Manifestations of Migraine with Dr. Hamid Djalilian https://www.backtable.com/shows/ent/podcasts/60/otologic-manifestations-of-migraine Dr. Hamid Djalilian University of California, Irvine Profile: https://www.ent.uci.edu/faculty/hamid-djalilian-md.asp Dr. Hamid Djalilian's Website: https://hamiddjalilianmd.com/ Fan-Gang Zeng (Hearing and Speech) Lab at UCI: https://faculty.sites.uci.edu/hesplab/ PearsonRavitz: https://pearsonravitz.com/

Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population. “Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities.” – Dr. Jeff Sharman, MD   “A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy.” – Dr. Jeff Sharman, MD    Jeff Sharman, MD  Medical Director of Hematology Research, US Oncology Director of Research Willamette Valley Cancer Institute Eugene, Oregon    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

Send us a textIn this Ones Ready Podcast episode, Aaron and Peaches sit down with Dr. Tim Vermillion to explore essential topics on mental health, stress management, and support for military veterans. Dr. Vermillion shares his personal journey from the military to becoming a therapist, offering valuable insights into the impact of stress on the body and mind. They delve into the importance of breath work, physical activity, and the early signs of unhealthy coping mechanisms. Dr. Vermillion explains therapeutic approaches like cognitive behavioral therapy (CBT) and eye movement desensitization and reprocessing (EMDR) for treating PTSD.The conversation also touches on groundbreaking treatments, including psychedelic therapies, hyperbaric therapy, and transmagnetic stimulation, with a focus on the VA's ongoing research. Dr. Vermillion emphasizes the critical role of active listening, non-confrontational support, and the military's efforts to destigmatize mental health struggles. He encourages veterans to seek help and be open about their challenges, offering hope through new and evolving therapies.Chapters00:00 Introduction and Background09:45 Understanding Stress and Its Management18:29 The Role of Breath Work and Physical Activity22:18 Recognizing Early Warning Signs of Unhealthy Coping26:23 Treating PTSD with CBT and EMDR32:23 Expanding Stress Tolerance34:18 Supporting Others in Managing Stress and Trauma34:31 Supporting Veterans' Mental Health36:05 Active Listening and Non-Confrontational Approaches37:02 Avoiding Directive Language38:09 Substances and Inhibiting the Healing Process40:29 Self-Medication and Negative Effects41:35 Comparing Substances: Alcohol, Tobacco, and Marijuana48:07 Destigmatizing Mental Health in the Military51:47 Following Mentors and Gaining Tacit KnowledgeSupport the showJoin this channel to get access to perks:https://www.youtube.com/channel/UC9aFBBZoBcQk8UUN_pO7nDA/joinBuzzsprout Subscription page: https://www.buzzsprout.com/680894/subscribeCollabs:Ones Ready - OnesReady.com 18A Fitness - Promo Code: 1ReadyATACLete - Follow the URL (no promo code): ATACLeteCardoMax - Promo Code: ONESREADYHoist - Promo Code: ONESREADYThe content provided is for informational purposes only and does not constitute legal advice. The host, guests, and affiliated entities do not guarantee the accuracy or completeness of the information provided. The use of this podcast does not create an attorney-client relationship, and the podcast is not liable for any damages resulting from its use. Any mention of products or individuals does not constitute an endorsement. All content is protected by intellectual property laws....

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.  “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf   

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma. “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC     Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf         

This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: The pros and cons of steroid use in treating AD Targeted non-steroidal topical therapies approved by the FDA Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals Recommendations for long-term symptom control in AD patients

In this episode of Causes or Cures, Dr. Eeks chats with cardiologist, physician-scientist and CEO of Fractyl Health Dr. Harith Rajagopalan about solutions his company is developing for the problem of keeping weight off after someone stops taking the obesity/weight loss medication, such as Ozempic. Dr. Rajagopalan explains the issue of weight rebound after stopping the medication, and describes two new therapies Fractyl Health is developing that would allow a person to sustain weight loss without the need for ongoing medication. He also provides an overview of the multifaceted approach necessary for tackling obesity and offers a unique perspective on chronic disease.  You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here. Support the Show.

Full show notes: https://syngap.fund/n142    BIG NHS UPDATE 66 Kids evaluated, 11 have had follow-ups, ~20 new kids scheduled. Colorado should start seeing patients in August! WHERE TO DONATE MONEY: MDBR is next week, donate now! https://charity.pledgeit.org/t/jY577u7uMc Thanks to the team. https://Syngap.Fund/Unite   BLOOD: June 7 & 8, Loews Coronado Bay Resort, email CSO@cureSYNGAP1.org TIME TO JOIN #TEAMSRF  - Volunteer Webinar: https://syngap.fund/LT - Fifty families lent their good names to SRF in this wonderful blog: https://syngap.fund/Community   - https://curesyngap1.org/volunteer-with-srf/    CHATS WITH INDUSTRY  - Is IT delivery a blocker for precision therapies, NO!  - 2026 is feeling like the earliest we see trials.  - BIO with Kathryn next week! CALENDAR MANAGEMENT Rare Across America is 66 days away, register now: https://everylifefoundation.org/rare-advocates/rare-across-america/    Conference is 188 days away: https://curesyngap1.org/events/conferences/syngap1-conference-2024/   PUBLICATION ALERT https://x.com/cureSYNGAP1/status/1795837761678962799    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources SOCIAL MATTERS - AMPLIFY SRF TO MAKE SURE FAMILIES FIND US  - 1,020 YouTube.  https://www.youtube.com/@CureSYNGAP1   - 10,000 Twitter https://twitter.com/cureSYNGAP1  - 3,591 LinkedIn.  https://www.linkedin.com/company/curesyngap1/ - 49k Insta https://www.instagram.com/curesyngap1/ - 392 TikTok https://www.tiktok.com/@curesyngap1 Podcasts, give all of these a five star review! SRF Channel - https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917 Episode 142 of #Syngap10 - May 31, 2024 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GeneChat #F78A1 #CureSYNGAP1

In this episode, Dr. Daniel Llano leads a discussion focusing on new therapy options for dementia patients.

There are developments in the world of men's health in erectile dysfunction and testosterone. As always Ray and I are dedicated to delivering the latest news and technology and today men's health gets a boost.     See omnystudio.com/listener for privacy information.

Pour accéder à l'intégralité de ce podcast et écouter chaque semaine un nouvel épisode du Quart d'Heure Véto, c'est très simple, il vous suffit de vous abonner en cliquant sur ce lien : https://m.audiomeans.fr/s/S-yUNSBZSR Notes et références Article Cox A, Stewart AJ. Insect Bite Hypersensitivity in Horses: Causes, Diagnosis, Scoring and New Therapies. Animals (Basel). 2023 Aug 4;13(15):2514. doi: 10.3390/ani13152514. PMID: 37570323; PMCID: PMC10416928. Retrouvez toute la synthèse sur la fiche podcast juste ici : https://audmns.com/uqtLWVt Pour nous suivre : 1. Abonnez-vous à notre chaine pour profiter de l'intégralité des épisodes : Le Quart d'Heure Véto : décrypte et résume en moins de 15 min un article de biblio véto - Sur abonnement uniquement Le Véto du Mois : Partagez le temps d'une interview l'expérience de vétérinaires emblématiques de notre milieu, des rencontres conviviales, comme si nous étions dans votre salon au coin du feu. Podcasts bonus au fil des inspirations... 2. Le Scope Nous partageons avec vous nos dernières découvertes, inspirations, pistes de réflexion, nouveautés… À découvrir et utiliser dès maintenant, TOUT DE SUITE, dans votre quotidien de vétérinaire, de manager, de vie personnelle, de chef d'entreprise… Et tout cela en moins de 5 minutes top chrono un à 2 mardis par mois ! Je souhaite recevoir mon Scope : https://vetmasterclass.com/lescope/ 3. Contactez-nous, suivez-nous et donnez nous votre avis ! Des sujets que vous souhaiteriez approfondir, des références à partager, ou nous faire part de vos feed-backs : Abonnez-vous à notre chaine, donnez nous des étoiles, un commentaire et partagez autour de vous ! Sur notre site : https://vetmasterclass.com/ Sur Facebook : https://www.facebook.com/VmHorse Sur Instagram : https://www.instagram.com/vetmasterclass/ Sur YouTube : https://www.youtube.com/channel/UC18ovcWk9e-mFiTL34OQ03g Sur Linkedin : https://www.linkedin.com/company/vetmasterclass-horse/about/ Belle journée à tous, Et continuez à vivre votre métier avec Passion !

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope… The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with LLS.

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope… The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with LLS. The post How New Therapies Are Changing The Future of Myeloma appeared first on The Bloodline with LLS.

IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD by Gastroenterology Learning Network

Learn from those with hands-on experience about what to expect with these new therapies, and prepare to use them appropriately. Credit available for this activity expires: 12/06/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/995806?ecd=bdc_podcast_libsyn_mscpedu

Featuring perspectives from Dr Richard T Penson and Dr Krishnansu S Tewari, including the following topics: Introduction: Pan-tumor Indications for New Therapies (0:00) Endometrial Cancer (14:13) Treatment of Cervical Cancer (32:38) Updates in Ovarian Cancer (45:41) CME information and select publications

Latest real-world evidence with long-durability therapies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Credit available for this activity expires: 10/23/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/997563?ecd=bdc_podcast_libsyn_mscpedu

How do retina specialists introduce new therapies to patients, and how does thoughtful use of imaging help providers integrate new treatments into their clinics? Moderator Aleksandra Rachitskaya, MD, joins panelists Mrinali Gupta, MD, and Katherine Talcott, MD, to review how innovations in imaging software have helped onboard GA therapies in real-world clinics. This episode is sponsored by ZEISS.

Drs Sandhya Srinivas and Oliver Sartor discuss the VISION study, new therapies for patients with metastatic castrate-resistant prostate cancer, and PSMA biomarker-based imaging. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988736). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Lutetium-177-PSMA-617 for Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/34161051/ Prostate Cancer Theranostics: PSMA Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/34053583/ Piflufolastat F-18 (18F-DCFPyL) for PSMA PET Imaging in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35603510/ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in Prostate Cancer https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients https://pubmed.ncbi.nlm.nih.gov/27765862/ Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression https://pubmed.ncbi.nlm.nih.gov/30425003/ Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients With Castration-resistant Prostate Cancer and Bone Metastases: Results From a Phase 3, Double-blind, Randomised Trial https://pubmed.ncbi.nlm.nih.gov/24836273/ Long-term Follow-up and Outcomes of Retreatment in an Expanded 50-patient Single-center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/31732676/ [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/33581798/ Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-label Trial https://pubmed.ncbi.nlm.nih.gov/20888992/ [177Lu]Lu-PSMA-617 in PSMA-positive Metastatic Castration-resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5001 PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-naïve Patients With Metastatic Castration-resistant Prostate Cancer https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.TPS211

CME credits: 1.00 Valid until: 25-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/roundtable-safety-and-efficacy-data-on-new-therapies-for-excessive-daytime-sleepiness-in-obstructive-sleep-apnea/16031/ This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

New biological therapies like dupilumab target Type 2 inflammation, but new research shows they are also modifying the skin microbiome. In this episode we discuss what Type 2 inflammation is, why it matter in eczema, and how it modifies the microbiome. Our guest is Dr. Lisa Beck (Co-Director of the Center for Allergic Disease Research, University of Rochester Medical Center, NY) who has dedicated her 35 year career to understanding why some eczema patients are susceptible to skin infections and finding safe and effective eczema treatments.Research associated with this podcastType 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic DermatitisTralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitisRapid Reduction in Staphylococcus aureus in Atopic Dermatitis Subjects Following Dupilumab Treatment

CME credits: 1.00 Valid until: 14-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/why-do-we-need-new-therapies-for-sickle-cell-disease/15708/ Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.

In this Healthed lecture, , Surgical Oncologist & General Surgeon, A/Prof Robyn Saw will desribe how to identify a high risk patient, key steps in doing an effective skin check, the ideal biopsy, the implications that sentinel lymph node biopsies have for therapy and when to refer your patients.See omnystudio.com/listener for privacy information.

Despite astonishing advances in science and technology over the last several decades, cancer remains one of the leading causes of death worldwide, with an estimated 9.96 million people dying from cancer in 2020. Dr Thomas Seyfried, a professor at Boston College and a prominent researcher and professor in the field of cancer biology and metabolic therapy, believes this is a result of a misunderstanding as to what cancer is. Over a decade ago, Seyfried, a trailblazer in the arena of conquering cancer, published his groundbreaking book Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer, which provided extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This theory has incredible implications for the development of new non-toxic cancer therapies. In an interview with Dr Seyfried, he explained the virtues of this concept, the dogmatic ideology that is suppressing its development in mainstream medicine, and how the current cancer treatment is killing patients. A stunning interview with thought-provoking revelations. Learn more about your ad choices. Visit megaphone.fm/adchoices

Psoriasis, atopic dermatitis, vitiligo...when it comes to chronic skin conditions, it can feel like the odds are stacked against you. But don't despair! There's a new player in the field that is changing the game: the Janus Kinase (JAK) family!  JAK inhibitors are used in patients with skin and other conditions where the immune system is overactive and causing damage. Tune in to this week's podcast episode with Dr. Chovatia, where we dive deep into the science behind JAK inhibitors and how they're helping patients manage their symptoms. Connect with Dr. Chovatia :- Linkedin- @rajmdphd Twitter- @RajMDPhD

Episode Notes Drs. Emily Kirkpatrick, Paul Sax, and Jill Strayer join Dr. Rachel Britt to discuss their experiences using injectable long-acting antiretrovirals, especially cabotegravir/rilpivirine, in their clinics. Listen to learn not only about logistical challenges with these drugs, but also creative solutions to overcome them. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

Allen Davidoff, PhD is the Founder and CEO of XORTX Therapeutics, Inc., a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. This podcast episodes looks at novel therapies in development that may extend kidney health.

Dr. Allen Davidoff is the founder and CEO of XORTX Therapeutics, exploring new therapies to treat progressive kidney disease. Educated at The University of Calgary, Allen has 15 years of drug development experience with a focus on clinical and regulatory developmental affairs in the US, Canada, Germany, Denmark, and India. Allen has a broad range of senior management experience in pharmaceutical research and development including involvement in two investigational new drug (“IND”) applications or supplemental IND's, two phase I studies, seven phase II studies, and one new drug application (NDA). Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp.  If you have questions regarding items discussed during this episode or would like more information about Kidney Solutions weekly Support Group, contact Kent at kent.bressler@kidneysolutions.org For more information about Kidney Solutions, visit them at www.kidneysolutions.org Host: Kent Bressler Producer: Jason Nunez

Dr. Lorenz Studer is the Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Institute. His lab exploits recent advances in stem cell biology to develop new therapies for degenerative diseases and cancer. Their projects involve directing the fate and age of hPSCs, modeling diseases, and developing cell therapies. He talks about his journey into the stem cell field and co-founding BlueRock Therapeutics. He also discusses the challenges of developing cell therapies at scale, strategies to target cognition loss in Parkinson's disease, and combining basic and translational research.

Joe Selvaggi talks with Pioneer Institute's Senior Fellow Dr. Bill Smith about the changes to drug pricing laws included in the recently passed Inflation Reduction Act. They discuss the legislation’s provisions, and who wins and loses as drug companies announce their response to the new law. Guest: William S. Smith is Visiting Fellow in Life […]

Joe Selvaggi talks with Pioneer Institute's senior fellow Dr. Bill Smith about the changes to drug pricing laws included in the recently passed Inflation Reduction Act provisions and discuss who wins and loses as drug companies announce their response to new law.

In this episode of the Gut Doctor podcast, Dr. Jenna Koliani-Pace, a gastroenterologist who specializes in inflammatory bowel disease, reviews two of the latest therapeutics to be approved by the FDA and discusses where they may fit in her clinical toolbox when treating Crohn's disease and ulcerative colitis.

ProFound Therapeutics has developed platform technology to catalogue and understand previously undetected human proteins and the role they play in health and disease. By focusing on proteins in the process of translation, the company said it has identified tens of thousands of undiscovered proteins that can provide untapped therapeutic targets. We spoke to Avak Kahvejian, co-founder and CEO of ProFound Therapeutics, about the company's platform technology, the vastness of the unexplored proteome it seeks to discover, and how this can lead to the development of breakthrough medicines.

In the first hour of "Connections with Evan Dawson" on Wednesday, November 23, 2022, the team from a company called NeuroGenesis discusses a developing therapy that may be able to treat neurodegenerative diseases like MS and ALS.

November is Lung Cancer Awareness Month. This is an important time of the year, which brings the community together to help provide awareness, and people about the symptoms of the disease. It is the fifth most common cancer in Australia, with thousands of Australians diagnosed with the disease each year. The estimated number of new cases of lung cancer diagnosed in 2022 is 14,529 of which 7,707 are males and 6,822 are females. We speak with Dr Salah Amedi from Perth about lung cancer and its causes. - Mijdar Meha Hişyariya Penceşêra Pişikê ye. Ev demeke girîng ya salê ye, ku civakê digihîne hev da ku alîkariya peydakirina hişyariyê bike, û agahdar bike û mirovan li ser nîşanên nexweşiyê agahdar bike. Ew pêncemîn kansêra herî berbelav li Australya ye, ku her sal bi hezaran Australî bi vê nixweşiyê têne teşxîs kirin. Hejmara texmînkirî ya dozên nû yên seretana pişikê di sala 2022 de hatine tespît kirin evin 14,529 ku 7,707 nêrin û 6,822 mê ne. Em derbarê vê mijarê bi Dr Selah Amêdî re dipeyvin.

CIRM-funded Alpha Stem Cell Clinics are a network California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., Ph.D., Sean Turbeville, Ph.D., and Leo D. Wang, M.D., Ph.D., then discuss current clinical trials and the future of stem cell research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38400]

CIRM-funded Alpha Stem Cell Clinics are a network California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., Ph.D., Sean Turbeville, Ph.D., and Leo D. Wang, M.D., Ph.D., then discuss current clinical trials and the future of stem cell research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38400]

CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., Ph.D., Sean Turbeville, Ph.D., and Leo D. Wang, M.D., Ph.D., discuss current clinical trials and the future of stem cell research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38400]

CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., Ph.D., Sean Turbeville, Ph.D., and Leo D. Wang, M.D., Ph.D., discuss current clinical trials and the future of stem cell research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38400]

Epidemiologist Steffanie Strathdee and her husband, psychologist Tom Patterson, were vacationing in Egypt when Tom came down with a stomach bug. What at first seemed like a case of food poisoning quickly turned critical, and by the time Tom had been transferred via emergency medevac to the world-class medical center at UC San Diego, where both he and Steffanie worked, blood work revealed why modern medicine was failing: Tom was fighting one of the most dangerous, antibiotic-resistant bacteria in the world.Steffanie joins Greg this episode to discuss solving her husband's medical crisis, and what she learned from this horrific experience. They also discuss how Covid has ramped these trends up, how critical phages are for our bodies, and the open mindedness of PhDs vs MDs.Steffanie is Associate Dean of Global Health Sciences and Harold Simon Distinguished Professor in the Department of Medicine at the University of California San Diego School of Medicine. She is also an Adjunct Professor at Johns Hopkins and Simon Fraser Universities. She co-directs UCSD's new center for Innovative Phage Applications and Therapeutics (IPATH), Global Health Institute and the International Core of UCSD's Center for AIDS Research. Stefanie has co-authored her memoir all about her husbands illness titled, “The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug.”Episode Quotes:The need for a phage library[30:40] What we need to do is build a phage library that maps onto a superbug library. And, of course, these are going to be constantly needing to be updated because these are organisms that are co-evolving to attack one another.What's the future looking for the advancement of phage[37:55] I can imagine a situation in the future, though, where, because we have, sequencers that are portable and cheaper than ever before, that you'd be able to sequence a phage and sequence a bacteria and be able to have a database to say, okay, you know, this phage will match that bacterium or to even genetically modify or synthesize a phage. So in a 3D printing model, some of my colleagues in Belgium have, you know, been working on that. So, I think that there's going to be advances that are going to help us make this work. But right now, we need phage libraries. We need more investment in clinical trials.Pushing beyond boundaries leads to discovery[39:49] When your back is up against the wall, whether it's you as an individual, us as a society, or a planet, we can sometimes have creative ideas to come up with solutions that we wouldn't otherwise do. And that's what I'm hoping that we'll do now because both climate change and antimicrobial resistance are colliding.Show Links:Guest Profile:Faculty Profile at UC San DiegoFaculty Profile at John Hopkins Bloomberg School of Public HealthProfessional Profile at Canadian Association for Global HealthSteffanie Strathdee on LinkedInSteffanie Strathdee on TwitterSteffanie Strathdee on InstagramSteffanie Strathdee on TEDxNashvilleHer Work:Steffanie Strathdee on Google ScholarThe Perfect Predator Website

Communication between the digestive system and brain is much more intricate than previously thought.  The digestive epithelium is laced with sensors that monitor the contents of the gut, reporting back to the brain, stimulating appropriate hormones and digestive action to guide motility, chemistry, and absorption. This network is frequently referred to as the 'second brain' because of the dense neurophysiology at work. Recently it has been hypothesized that dysfunction in the gut-brain axis may be the basis for several immune and neurological disorders, suggesting that this neurological system may be an excellent drug target. Nancy Thornberry, CEO and Founder of Kallyope (Cal-EE-O-pay) describes the gut-brain axis, its role in digestive signaling, her company's novel drug discovery methods, and potential drug targets that may lead to innovative therapies for human health originating here in the second brain. 

Question Time: Applying New Therapies for the Management of mTNBC

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.

A discovery by Harvard University researchers found that a commonly available drug stops formation of the material that hardens arteries in heart disease. Environmental health expert Douglas Mulhall breaks it down for us.Support this podcast at — https://redcircle.com/local-news-live-daily/donationsAdvertising Inquiries: https://redcircle.com/brands

A discovery by Harvard University researchers found that a commonly available drug stops formation of the material that hardens arteries in heart disease. Environmental health expert Douglas Mulhall breaks it down for us.Support this podcast at — https://redcircle.com/local-news-live-daily/donationsAdvertising Inquiries: https://redcircle.com/brands